Evidence review

NAD+ Therapy: Strong Biology, Weak Clinical Evidence

NAD+ is a genuinely important coenzyme and its decline with age is well documented. What does not follow is that supplementing it produces the clinical benefits marketed

Dr. Parmis, Editorial Lead · Jonathan Michael Snipes, MD, Medical Reviewer

Published 2026-07-26Updated 2026-07-26Sources captured 2026-07-26Medically reviewed not yet — why

Direct answer

NAD+ is a genuinely important coenzyme and its decline with age is well documented. What does not follow is that supplementing it produces the clinical benefits marketed for it. Human trials of NAD+ precursors have reliably raised blood NAD+ levels and have not reliably produced functional benefit.

Answer last reviewed: 2026-07-26

The biology is real

NAD+ is a coenzyme central to cellular energy metabolism and to the function of sirtuins and PARPs. Tissue NAD+ declines with age across multiple species, and restoring it in animal models produces measurable effects on metabolic and mitochondrial function.

None of that is controversial, and it is why the field attracted serious research investment rather than only commercial interest.

Where the evidence stops

Human trials of NAD+ precursors — nicotinamide riboside and nicotinamide mononucleotide — have consistently shown that oral supplementation raises circulating NAD+ levels. That is a pharmacokinetic finding: the compound gets in and does what it is supposed to biochemically.

What those trials have generally not shown is corresponding clinical benefit on hard endpoints. Improvements in muscle function, insulin sensitivity, cognitive performance and biomarkers of ageing have been inconsistent, small, or absent depending on the trial and population.

That pattern — target engagement without clinical benefit — is one of the most common outcomes in translational research, and it is the single most important thing to understand about this category.

The IV question

NAD+ administered intravenously is marketed at a substantial premium over oral precursors. The rationale offered is bioavailability.

What is missing is any demonstration that raising NAD+ faster or higher produces outcomes that oral precursors do not. If the limiting factor were blood levels, oral trials that successfully raised blood levels should have produced benefit. They largely did not.

Infusions also carry the ordinary risks of intravenous access, and the reported experience during infusion is frequently unpleasant at higher rates.

How to read a NAD+ claim

Does the cited study measure NAD+ levels, or does it measure an outcome a patient would notice?
Is it a human randomised trial, or animal work, or an uncontrolled series?
What was the population, and does it resemble you?
Is the effect size clinically meaningful, or statistically detectable but small?

Most marketing in this category relies on the first question being answered "levels" and the reader not noticing.

FDA docket 2026-08552 — status nowEvaluated 2026-07-26

FDA docket 2026-08552 — status now
Field	Detail
Status	Open Verified
Time remaining	4 days remain. Comments must be submitted by 2026-07-30. Anyone may comment: patients, clinicians, pharmacies and the public. Late filings are not considered.
What is proposed	Excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List, on a finding of no clinical need
Notice	91 FR 23431, published 1 May 2026
Original deadline	29 to 30 June 2026, a 60-day period
Extended deadline	2026-07-30, following a request for a 60-day extension
Who it binds	503B outsourcing facilities. Section 503A patient-specific compounding is a separate pathway and is not addressed
Shortage pathway	Unchanged: 503B facilities may still compound during a declared shortage
How to comment	Through the federal docket, or in writing to the contact of record at CDER
Contact of record	Tracy Rupp, Center for Drug Evaluation and Research, [email protected]

This block recomputes its own status at every build rather than asserting a state that goes stale. The deadline was extended once already, so treat it as the current position rather than a final one.

The thirteen gates a page clears before it publishes

Show this figure as a table

Data table
Step	Stage	What happens
1	Search intent match	Does the page answer the question actually being asked?
2	Original value test	What exists here that is not already on ten other sites?
3	Source and evidence review	Every claim resolves to a ledger entry with a capture date.
4	Medical review	A named clinician checks claims against their primary sources.
5	Pricing verification	Figures re-captured from the provider's own page, dated.
6	Conflict-of-interest review	Any relationship that could bias the page, declared.
7	Legal and regulatory language	No implied approval, no generic claim, no individual advice.
8	Accessibility review	WCAG 2.2 AA, keyboard, contrast, chart data tables.
9	Mobile QA	390px viewport hides no fee, qualifier, status or date.
10	Structured-data validation	JSON-LD matches what a reader can see.
11	Internal-link validation	Parent hub, methodology, siblings, tool or dataset.
12	Duplication and cannibalisation check	No two pages chasing the same intent.
13	Date and cadence assignment	Review dates set from real work, not from the calendar.

A draft that fails one gate does not publish partially. It waits.

What each step actually changedPrimary sources · captured 2026-07-26

What each step actually changed
Date	What happened	Effect on compounded access
2022	Tirzepatide added to the FDA drug shortage list	A shortage listing is what permitted compounders to make copies of the approved product.
2024-10	FDA declared the tirzepatide shortage resolved	Removing the shortage listing removed one of the two legal pathways for compounding tirzepatide.
2025-02	FDA declared the semaglutide shortage resolved	The same pathway closed for semaglutide four months later.
2025-09-16	FDA issued 55+ warning letters to online GLP-1 sellers	Letters cited misleading direct-to-consumer advertising of compounded GLP-1 products.
2026-02-09	Novo Nordisk sued Hims & Hers over compounded semaglutide	Patent infringement claim following the launch of a low-cost compounded oral product.
2026-03-03	FDA released 30 further warning letters to telehealth firms	Targeting claims that compounded GLP-1s are equivalent to the branded products.
2026-03-09	Hims & Hers settled with Novo Nordisk and pivoted to branded supply	Hims agreed to offer branded semaglutide and cease most compounded GLP-1 marketing. The largest compounded seller in the category left it. This changes who is actually in the compounded market.
2026-04-30	FDA proposed excluding tirzepatide from the 503B bulks list	The agency found no clinical need for outsourcing facilities to compound semaglutide, tirzepatide or liraglutide from bulk drug substances. This proposal targets the second and last remaining pathway.
2026-05-01	Formal notice published at 91 Fed. Reg. 23431	Docket 2026-08552 sets out the agency's substance-by-substance reasoning.
2026-06-26	Comment period extended to 30 July 2026	FDA granted an extension after a request for more time to respond. Comments inform, but do not bind, the final determination.
2026-07-30	Comment period closes	After this date the agency considers submissions before making a final determination. No final determination had published as of 24 July 2026.

A proposal is not a final rule. Nothing here says compounded tirzepatide is unlawful today.

503A pharmacy against 503B outsourcing facilityStatutory distinction · pending legal review

503A pharmacy against 503B outsourcing facility
Requirement	503A compounding pharmacy	503B outsourcing facility
Compounds pursuant to	A prescription for an identified individual patient	May compound without patient-specific prescriptions
FDA registration	Not registered as an outsourcing facility	Registers with FDA
CGMP requirements	Not required to meet CGMP	Must comply with CGMP — though registration alone is not evidence of compliance
Primary oversight	State board of pharmacy	FDA, on a risk-based inspection schedule
Adverse-event reporting	Not required under 503A	Required to report adverse events to FDA
Product approval status	Not an FDA-approved product	Not an FDA-approved product
What registration establishes	Not applicable	FDA received the required information, nothing more Verified

Neither route produces an FDA-approved medicine. Registration and inspection are not approval, and no accreditation changes that.

Questions readers actually ask

Does NAD+ therapy work?

Human trials of NAD+ precursors reliably raise blood NAD+ levels. They have not reliably produced clinical benefit on hard endpoints.

Is IV NAD+ better than oral?

No trial has demonstrated that raising NAD+ faster or higher produces outcomes oral precursors do not. Oral trials that successfully raised levels largely did not produce benefit.

Is NAD+ regulated as a drug?

NAD+ and its precursors are sold in several regulatory categories depending on formulation and claims. Injectable preparations prepared by a compounding pharmacy require a prescription.

The 100-point rubricCore & Trust
Cost calculatorTools
The underlying price recordsData
SURMOUNT-4: Weight Maintenance and Tirzepatide WithdrawalResearch
SURMOUNT-3 Tirzepatide Trial ExplainedResearch
SURMOUNT-1 Tirzepatide Trial ExplainedResearch
SUMMIT Trial: Tirzepatide and HFpEFResearch
Retatrutide Phase 3 Results: What Changed in July 2026Journal
Retatrutide Phase 3 Results and How It ComparesResearch
Oral Tirzepatide and Sublingual Products: What Evidence Exists?Pillar / Money

Cite this pageCC BY 4.0

Tirzepatide Ranked. “NAD+ Therapy: Strong Biology, Weak Clinical Evidence.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/peptides/nad-plus/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error